Table 4. Association analysis of rs1805812 x rs625245 interactions between MRE11A and NBS1 with the risk of NHL.
| NBS1 (rs1805812)/ | Stage 1 | Stage 2 | Stage 1 & 2 [Aggregate] | |||||||
| MRE11A (rs625245) genotype | Cases | Controls | OR (95% CI) | Cases | Controls | OR (95% CI) | Cases | Controls | OR (95% CI) | |
| Model 1 | ||||||||||
| NBS1 TT/MRE11A AA | 148 | 246 | 1.0 (Ref) | 205 | 278 | 1.0 (Ref) | 353 | 524 | 1.0 (Ref) | |
| NBS1 TT/MRE11A CA,CC and NBS1 CT,CC/MRE11A AA | 236 | 334 | 1.17 (0.90–1.53) | 222 | 354 | 0.85 (0.66–1.09) | 458 | 688 | 0.99 (0.83–1.18) | |
| NBS1 CT,CC/MRE11A CA,CC | 13 | 46 | 0.47 (0.25–0.90) | 19 | 48 | 0.53 (0.31–0.94) | 32 | 94 | 0.51 (0.33–0.77) | |
| P for interaction | 0.4211 | 0.02209 | 0.03183 | |||||||
| Model 2 | ||||||||||
| NBS1 TT,CT/MRE11A AA,CA | 367 | 556 | 1.0 (Ref) | 415 | 628 | 1.0 (Ref) | 782 | 1184 | 1.0 (Ref) | |
| NBS1 CC/MRE11A AA,CA,CC and NBS1 TT,CT/MRE11A CC | 30 | 70 | 0.65 (0.42–1.02) | 31 | 52 | 0.90 (0.57–1.43) | 61 | 122 | 0.76 (0.55–1.04) | |
| P for interaction | 0.03877 | 0.2747 | 0.03051 | |||||||
| Model 3 | ||||||||||
| NBS1 TT,CT,CC/MRE11A AA and NBS1 TT/MRE11A CA,CC | 384 | 580 | 1.0 (Ref) | 427 | 632 | 1.0 (Ref) | 811 | 1212 | 1.0 (Ref) | |
| NBS1 CT,CC/MRE11A CA,CC | 13 | 46 | 0.43 (0.23–0.80) | 19 | 48 | 0.59 (0.34–1.01) | 32 | 94 | 0.51 (0.34–0.77) | |
| P for interaction | 0.00436 | 0.01478 | 0.0002523 | |||||||
OR = odds ratio; CI = confidence interval.